Australia, April 24 -- Quince Therapeutics Inc., owns the trademark (2345587) for 'QUINCE' till Oct. 27, 2032.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical, medicinal and biological preparations for the treatment and prevention of Alzheimer's, brain disorders, neurological disorders, arthritis, infectious disease, genetic disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), autoimmune disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), inflammatory disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), diabetes, cancer, periodontal disease, blood disorders, pain, inflammation (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), sepsis, alopecia, obesity and cognitive disorders; pharmaceutical, medicinal and biological preparations for the treatment and prevention of orthopedic diseases and disorders; none of the foregoing goods being in the nature of nutraceuticals.], 42 [Medical and scientific study and research; pharmaceutical research and development; pharmaceutical and biological research, testing, and product development consultation; conducting clinical trials for others in the fields of Alzheimer's, brain disorders, neurological disorders, arthritis, infectious disease, genetic disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), autoimmune disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), inflammatory disease (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), diabetes, cancer, periodontal disease, blood disorders, pain, inflammation (not relating to hay fever, stomach ulcers, digestive disorders, cardiological conditions or tissue wounds), sepsis, alopecia, obesity and cognitive disorders; none of the foregoing services being in respect of treatments or products involving quince or in respect of nutraceuticals.], 05 [Pharmaceutical, medicinal and biological preparations for the treatment and prevention of Alzheimer's, brain disorders, neurological disorders, arthritis, infectious disease, genetic disease, autoimmune disease, inflammatory disease, diabetes, cardiovascular disease, cancer, periodontal disease, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders], 42 [Medical and scientific study and research; pharmaceutical research and development; pharmaceutical and biological research, testing, and product development consultation; conducting clinical trials for others in the fields of Alzheimer's, brain disorders, neurological disorders, arthritis, infectious disease, genetic disease, autoimmune disease, inflammatory disease, diabetes, cardiovascular disease, cancer, periodontal disease, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders] and 05 [Pharmaceutical, medicinal and biological preparations for the treatment and prevention of orthopedic diseases and disorders]
Type of Mark: Word
Date of Acceptance: Feb. 14
Registration Advertised: April 23
For further details contact ALLENS PATENT & TRADE MARK ATTORNEYS and Jeffrey Greene.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2345587.
Disclaimer: Curated by HT Syndication.
